1. RELAPSE İN DRUG-SENSİTİVE PULMONARY TB PATİENTS
Üsküdar Dispenser ………….Dr. Bektaş Kısa Beykoz Dispenser………… Dr. Sinem Köyman Kumkapı Dispenser………… Dr. Canan Küçük Şehremini Dispenser…………Dr. Nesrin Sarımurat İ. U. İstanbul Medical Faculty…..Prof. Dr. Zeki Kılıçaslan

2. Aim
The aim of this retrospective study is to determine the relapse rates in TB patients.

3. Findings Total number of patients (pulmonary + extrapulmonary ) 1100
Treatment success rate for all patients
% 91,5
(1007/1100)
Cure rate for smear (+) new patients
%85,7
(373/435)
Kumkapı VSD
Şehremini VSD
Beykoz VSD
Üsküdar VSD

4. Material andMethod

5. Material and Method
All patients were contacted by telephone, those who were not reached had letters sent by mail.
Those who had no clinical complaint or stabil x-rays were accepted as no relapse.
18 suspicious patients were evaluated with smears which were negative.
Some patients who repeatedly stated they had no complaints were unable to come to the dispensers. These patients family members were questioned and verified the patients good health.

6. Material and Method

7. Material and Method

8. Method
Thoses who were drug resistant or not tested were left out of this study.

9. Material and Method

10. 414 olgu : 21,7 ay Material and Method Pulmonary TB,
Smear (+) and/or Culture (+),
Drug-sensitive patients,
414 olgu :
Average age : 36,6 (11-80)
Average follow up period after treatment :
21,7 ay

11. Material and Method

12. Findings DOTS Partial or no DOTS Total New patients % 0,9 % 1,7 % 1,2
% 0,9
(2/226)
% 1,7
(2/120)
(P> 0,05)
% 1,2
(4/346)
Previously treated patients
% 2,4
(1/42)
% 11,1
(3/27)
(P>0,05)
% 5,9
(4/68)
RELAPS
3 patients
5 patients
% 1,9
(8/414)
NOT: The Ficher test was used for the determination of data differences

13. All relaps patients were proven with smear or culture positivity.
Findings
Smear (+)
Smear (-)
Culture (+)
TOTAL
NEW 2 4
PREVİOUSLY TREATED 8
All relaps patients were proven with smear or culture positivity.

14. Conclusion İn this study;
Four İstanbul dispensers with an average treatment success rate of 91.5% have acceptable relaps rates.
With DOT relaps rates were found to be lower (although not statistically significant) especially in previously treated patients.